Indegene
Corporate brand
UnclaimedHealthcare technology, research, and commercialization services company serving biopharmaceutical and healthcare organizations.
Last updated August 24, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Indegene Limited is an India-based healthcare technology and services company that works with biopharmaceutical companies, healthcare enterprises, and related organizations. Its activities span the commercial, clinical, medical, regulatory, and market-access sides of the healthcare value chain. Rather than operating primarily as a conventional pharmaceutical manufacturer or hospital network, Indegene provides specialist services, consulting, technology platforms, and operational support intended to help healthcare companies develop products, meet regulatory obligations, communicate medical information, and commercialize therapies. The company was established in 1998 by Rajesh Nair, Manish Gupta, Gaurav Kapoor, Sanjay Parikh, and Anand Kiran. It developed from an India-based services business into an international provider with operations and offices across India, the United States, Europe, and the Asia-Pacific region. Its work has included pharmaceutical marketing consulting, multichannel engagement, clinical-trial support, pharmacovigilance, medical affairs, regulatory affairs, health informatics, continuing medical education, market-access strategy, and pricing-related services. Indegene expanded partly through acquisitions. Its early acquisition of Medsn, a medical-education business, was followed by the acquisition of MedCases in 2006. Medsn continued operating in the United States before being renamed Indegene Pharmaceutical Solutions in 2008. In 2010, Indegene acquired Aptilon, a Canadian multichannel marketing company, adding capabilities in digital and coordinated engagement with healthcare professionals. The company later acquired Atlanta-based Total Therapeutic Management in 2014, London-based consulting firm DT Associates in 2019, and U.S.-based Medical Marketing Economics in 2021. These transactions broadened its presence in commercial strategy, consulting, market access, and pricing. The company entered a new ownership and financing phase in 2021 when Carlyle and Brighton Park Capital invested in Indegene. It subsequently pursued a public-market listing in India. Indegene completed its initial public offering in May 2024 and was listed on the Bombay Stock Exchange and the National Stock Exchange of India. The offering marked a transition from a privately financed specialist services company to a publicly traded healthcare-services enterprise. Indegene positions itself as a technology-enabled partner for life-sciences and healthcare organizations. Its value proposition combines domain expertise in medicine, pharmaceuticals, and regulation with digital systems, data, analytics, and operational delivery. The company’s customers and projects may require support at different stages of a therapy’s lifecycle, from clinical development and regulatory preparation through launch planning, commercial engagement, medical communications, and post-market activities. Publicly available reference material does not establish a single consumer-facing flagship product; the brand is primarily associated with business-to-business services and solutions. Indegene has also received workplace recognition in India, with The Economic Times naming it among the best companies to work for in the professional-services category in 2011 and 2012.
History
Indegene was founded in 1998 in India by Rajesh Nair, Manish Gupta, Gaurav Kapoor, Sanjay Parikh, and Anand Kiran. From its early development, the company focused on providing specialized services to pharmaceutical and healthcare organizations rather than producing medicines or operating healthcare facilities. Its service model combined healthcare and life-sciences knowledge with outsourced business processes, consulting, and technology-enabled delivery. An early area of expansion was medical education. Indegene acquired Medsn, a company providing medical education services in the United States. Medsn initially retained its own operating identity, but in 2008 it was formally renamed Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene also acquired MedCases, another U.S.-based continuing medical education company. These transactions helped establish a broader platform for medical communications and education services. The company continued building its commercial-services business during the late 2000s. In 2009, it signed a master service agreement with six pharmaceutical companies. In 2010, it acquired Aptilon, a Canadian multichannel marketing firm, for reported consideration of $4 million. Aptilon added capabilities related to coordinated pharmaceutical marketing and multichannel engagement. Indegene subsequently expanded its U.S. presence through the acquisition of Atlanta-based Total Therapeutic Management in 2014. The company’s international consulting footprint grew further in 2019, when it acquired DT Associates, a London-based consulting company. The transaction broadened Indegene’s ability to support healthcare and biopharmaceutical clients in consulting and related commercial activities. In February 2021, Carlyle and Brighton Park Capital invested $200 million in the company. Later that year, in August, Indegene acquired Medical Marketing Economics, a U.S. market-access and pricing-strategy business, for reported consideration of $10 million. The acquisition reinforced Indegene’s presence in pricing, reimbursement, and market-access work. Indegene entered the public markets in May 2024 through an initial public offering in India. The offering raised ₹1,842 crore, reported in reference material as approximately $190 million, and the company’s shares were listed on the Bombay Stock Exchange and the National Stock Exchange. This listing represented a significant corporate milestone and provided a public-market structure after the company’s period of private investment and acquisition-led growth. Operationally, Indegene serves organizations across several stages of the healthcare product lifecycle. Its areas of work include pharmaceutical marketing, clinical trials, pharmacovigilance, medical affairs, regulatory affairs, health informatics, continuing medical education, market-access planning, and pricing strategy. The company has offices or operations in India, the United States, the European Union, and the Asia-Pacific region. Public reference material also records workplace recognition from The Economic Times, which named Indegene among the best companies to work for in the professional-services category in both 2011 and 2012. No substantiated scandal or major regulatory controversy is identified in the supplied reference material.
- 2024
Initial public offering and stock-market listing
[1]Indegene completes an Indian initial public offering and lists on the BSE and NSE.
- 2021
Investment by Carlyle and Brighton Park Capital
[1]Carlyle and Brighton Park Capital invest in Indegene.
- 2021
Acquisition of Medical Marketing Economics
[1]Indegene acquires the U.S. market-access and pricing-strategy company Medical Marketing Economics.
- 2019
Acquisition of DT Associates
[1]Indegene acquires London-based consulting company DT Associates.
- 2014
Acquisition of Total Therapeutic Management
[1]Indegene acquires Atlanta-based Total Therapeutic Management.
- 2012
Second year of workplace recognition
[1]The Economic Times again recognizes Indegene among the best companies to work for in professional services.
- 2011
Professional-services workplace recognition
[1]The Economic Times names Indegene among the best companies to work for in the professional-services category.
- 2010
Acquisition of Aptilon
[1]Indegene acquires Canadian multichannel marketing firm Aptilon.
- 2009
Master service agreement with six pharmaceutical companies
[1]Indegene signs a master service agreement covering six pharmaceutical companies.
- 2008
Medsn becomes Indegene Pharmaceutical Solutions
[1]The acquired U.S. medical-education business Medsn is formally renamed Indegene Pharmaceutical Solutions.
Products and positioning
A technology-enabled healthcare and life-sciences services partner supporting biopharmaceutical organizations across clinical development, medical and regulatory affairs, commercialization, market access, and healthcare informatics.
Pharmaceutical commercialization
Commercial services
Indegene supports biopharmaceutical and healthcare organizations with commercial planning, pharmaceutical marketing, customer engagement, and multichannel activities. These services are designed for business-to-business clients and may support products across launch planning, market development, and ongoing engagement with healthcare stakeholders. The company’s acquisition of Aptilon expanded its multichannel marketing capabilities.
Clinical research support
Clinical development services
Indegene provides services connected with clinical development and clinical trials for healthcare and biopharmaceutical organizations. The supplied references identify clinical-trial support as part of the company’s portfolio, but do not specify individual platforms, therapeutic-area products, or proprietary clinical technologies.
Medical and regulatory services
Medical and regulatory affairs services
This service area covers support for medical affairs, regulatory affairs, medical communications, and related pharmaceutical activities. It draws on Indegene’s healthcare domain expertise and is intended to help clients prepare information, manage regulated processes, and communicate scientific and medical content.
Drug safety
Pharmacovigilance services
Indegene identifies pharmacovigilance as one of its healthcare services. The offering supports drug-safety activities for biopharmaceutical clients, although the supplied sources do not provide detailed information on specific systems, jurisdictions, or service modules.
Healthcare consulting · 2021
Market access and pricing strategy
Indegene provides market-access and pricing-related consulting for healthcare and biopharmaceutical organizations. The company strengthened this capability through its 2021 acquisition of Medical Marketing Economics, a U.S. business specializing in market access and pricing strategy.
Medical education
Medical education services
Medical education was an early area of Indegene’s expansion through its acquisition of Medsn and later acquisition of MedCases. These activities include continuing medical education and related medical-information services for healthcare audiences. Medsn operated in the United States before becoming Indegene Pharmaceutical Solutions in 2008.
Brand decisions
2024
Initial public offeringOtherBackground
After institutional investment and acquisition-led international expansion, Indegene pursued access to Indian public equity markets.
Action taken
Indegene completed an initial public offering and listed on the BSE and NSE.
Aftermath
The company became publicly traded in India. The offering raised ₹1,842 crore, reported in the reference material as approximately $190 million.
IPO proceeds. ₹1,842 crore (May 2024)
2021
Acquisition of Medical Marketing EconomicsM&ABackground
Indegene wanted to deepen its market-access and pricing-strategy capabilities.
Action taken
Indegene acquired U.S.-based Medical Marketing Economics.
Aftermath
The acquisition added specialist expertise in market access and pricing strategy. Reported consideration was $10 million.
Acquisition consideration. $10 million (2021)
2019
Acquisition of DT AssociatesM&ABackground
Indegene aimed to strengthen its international consulting capabilities.
Action taken
The company acquired London-based consulting firm DT Associates.
Aftermath
The acquisition expanded Indegene’s consulting presence in Europe. Reported consideration was $10 million.
Acquisition consideration. $10 million (2019)
2010
Acquisition of AptilonM&ABackground
Indegene sought to expand its pharmaceutical marketing and multichannel engagement capabilities.
Action taken
The company acquired Aptilon, a Canada-based multichannel marketing firm.
Aftermath
The transaction broadened Indegene’s commercial-services offering. Reported consideration was $4 million.
Acquisition consideration. $4 million (2010)
Recent events
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/indegene · Editorial policy · How profiles are compiled